Clinical trial results:
An Open-Label, Multicenter, Dose Escalation Phase Ib Study with Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination with Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients with Metastatic Solid Tumors

Summary

EudraCT number	2015-003480-11
Trial protocol	
Global end of trial date	30 October 2019

Results information

Result version number	v1 (current)
This version publication date	
First version publication date	

Trial information

Trial identification

Sponsor protocol code	BP29889

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02665416
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 October 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	30 October 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objectives of the study were to assess the safety, tolerability and therapeutic activity of selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to standard treatment.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 January 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 45
Country: Number of subjects enrolled	United States: 4
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	Denmark: 13
Country: Number of subjects enrolled	Netherlands: 23
Worldwide total number of subjects	94
EEA total number of subjects	82

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	67
From 65 to 84 years	27

85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at sites in Belgium, Canada, Denmark, Spain, Netherlands and USA.

Pre-assignment

Screening details:

Part I: Histologically confirmed advanced/metastatic solid tumors not amenable to standard therapy.
Part II: HNSCC or NSCLC or aPROC not amenable to standard therapy.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab

Arm description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1-8 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as concentrate solution during Part I to be administered via SC injection.

Investigational medicinal product name	Vanucizumab
Investigational medicinal product code	
Other name	RO5520985
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Vanucizumab was provided as solution to be administered via IV infusion.

Arm title	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab

Arm description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 12-18 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Arm type	Experimental

Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as concentrate solution during Part I to be administered via SC injection.

Investigational medicinal product name	Vanucizumab
Investigational medicinal product code	
Other name	RO5520985
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Vanucizumab was provided as solution to be administered via IV infusion.

Arm title	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab

Arm description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 24-32 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as concentrate solution during Part I to be administered via SC injection.

Investigational medicinal product name	Vanucizumab
Investigational medicinal product code	
Other name	RO5520985
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Vanucizumab was provided as solution to be administered via IV infusion.

Arm title	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab

Arm description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 40-72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Concentrate for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as concentrate solution during Part I to be administered via SC injection.

Investigational medicinal product name	Vanucizumab
Investigational medicinal product code	
Other name	RO5520985
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Vanucizumab was provided as solution to be administered via IV infusion.

Arm title	Part II: Selicrelumab + Bevacizumab (HNSCC)

Arm description:

Participants diagnosed with head and neck squamous cell carcinoma (HNSCC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as a solution for injection during Part II to be administered via SC injection.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab was administered via IV infusion.

Arm title	Part II: Selicrelumab + Bevacizumab (NSCLC)

Arm description:

Participants diagnosed with checkpoint-inhibitor (CPI)-experienced non-squamous non-small cell lung cancer (NSCLC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as a solution for injection during Part II to be administered via SC injection.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab was administered via IV infusion.

Arm title	Part II: Selicrelumab + Bevacizumab (aPROC)

Arm description:

Participants diagnosed with advanced platinum-resistant ovarian cancer (aPROC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Arm type	Experimental
Investigational medicinal product name	Selicrelumab
Investigational medicinal product code	
Other name	RO7009789
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Selicrelumab was provided as a solution for injection during Part II to be administered via SC injection.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bevacizumab was administered via IV infusion.

Number of subjects in period 1	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab
Started	16	14	10
Completed	16	14	10

Number of subjects in period 1	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)
Started	19	11	11
Completed	19	11	11

Number of subjects in period 1	Part II: Selicrelumab + Bevacizumab (aPROC)
Started	13
Completed	13

Baseline characteristics

Reporting groups

Reporting group title	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1-8 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 12-18 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 24-32 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 40-72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Part II: Selicrelumab + Bevacizumab (HNSCC)

Reporting group description:

Participants diagnosed with head and neck squamous cell carcinoma (HNSCC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Part II: Selicrelumab + Bevacizumab (NSCLC)

Reporting group description:

Participants diagnosed with checkpoint-inhibitor (CPI)-experienced non-squamous non-small cell lung cancer (NSCLC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Part II: Selicrelumab + Bevacizumab (aPROC)

Reporting group description:

Participants diagnosed with advanced platinum-resistant ovarian cancer (aPROC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab
Number of subjects	16	14	10
Age categorical Units: Subjects			
Adults (18-64 years)	13	13	7
From 65-84 years	3	1	3
Age Continuous Units: Years			
arithmetic mean	52.3	49.9	60.1
standard deviation	± 10.8	± 13.1	± 10.5
Gender categorical Units: Subjects			
Female	9	4	7
Male	7	10	3

Reporting group values	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)
Number of subjects	19	11	11
Age categorical Units: Subjects			
Adults (18-64 years)	12	5	6
From 65-84 years	7	6	5
Age Continuous Units: Years			
arithmetic mean	60.3	61.7	60.9
standard deviation	± 12.0	± 6.1	± 10.6
Gender categorical Units: Subjects			
Female	13	1	7
Male	6	10	4

Reporting group values	Part II: Selicrelumab + Bevacizumab (aPROC)	Total	
Number of subjects	13	94	
Age categorical Units: Subjects			
Adults (18-64 years)	11	67	
From 65-84 years	2	27	
Age Continuous Units: Years			
arithmetic mean	58.4		
standard deviation	± 7.2	-	
Gender categorical Units: Subjects			
Female	13	54	
Male	0	40	

End points reporting groups

Reporting group title	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1-8 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 12-18 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 24-32 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 40-72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Part II: Selicrelumab + Bevacizumab (HNSCC)

Reporting group description:

Participants diagnosed with head and neck squamous cell carcinoma (HNSCC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Part II: Selicrelumab + Bevacizumab (NSCLC)

Reporting group description:

Participants diagnosed with checkpoint-inhibitor (CPI)-experienced non-squamous non-small cell lung cancer (NSCLC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Part II: Selicrelumab + Bevacizumab (aPROC)

Reporting group description:

Participants diagnosed with advanced platinum-resistant ovarian cancer (aPROC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Subject analysis set title	Part I: Selicrelumab 1-72 mg + Vanucizumab
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1 to 72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Part II: Selicrelumab 16 mg + Bevacizumab
Subject analysis set type	Safety analysis

Subject analysis set description:

Participants received bevacizumab at dose 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection after the bevacizumab infusion on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (approximately 18 months).

Subject analysis set title	Selicrelumab 1 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 2 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 2 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 4 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 4 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 8 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 8 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 12 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 12 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 14 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 14 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every

third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Part II: Selicrelumab 16 mg + Bevacizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received bevacizumab at dose 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection after the bevacizumab infusion on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (approximately 18 months).

Subject analysis set title	Selicrelumab 18 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 18 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 24 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 24 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 32 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 32 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 40 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 40 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 48 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 48 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Subject analysis set title	Selicrelumab 72 mg + Vanucizumab
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months).

Primary: Part I: Percentage of Participants With Dose-Limiting Toxicities (DLTs)

End point title	Part I: Percentage of Participants With Dose-Limiting Toxicities (DLTs)[1][2]

End point description:

DLTs were evaluated based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v 4.03). DLT was defined as an adverse event or abnormal laboratory value, (judged clinically significant by the investigator) considered related to selicrelumab and/or vanucizumab that occurred during the first 28 days of treatment. Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication.

End point type	Primary

End point timeframe:

From Day 1 until Day 28 of Cycle 1 (cycle length=28 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: percentage of participants				
number (not applicable)	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part I: Maximum Tolerated Dose (MTD) of Selicrelumab in Combination With Vanucizumab

End point title	Part I: Maximum Tolerated Dose (MTD) of Selicrelumab in Combination With Vanucizumab[3]

End point description:

MTD was defined as the dose level for which the probability of DLT was equal to a protocol-specified target probability. DLTs were evaluated based on the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v 4.03). DLT was defined as an adverse event or abnormal laboratory value, (judged clinically significant by the investigator) considered related to selicrelumab and/or vanucizumab that occurred during the first 28 days of treatment. Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication. 99999=not determined

End point type	Primary

End point timeframe:

From Day 1 until Day 28 of Cycle 1 (cycle length=28 days)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

End point values	Part I: Selicrelumab 1-72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	59			
Units: milligrams (mg)				
number (not applicable)	99999			

Statistical analyses

No statistical analyses for this end point

Primary: Part I: Recommended Phase II Dose (RP2D) of Selicrelumab in Combination With Vanucizumab

End point title	Part I: Recommended Phase II Dose (RP2D) of Selicrelumab in Combination With Vanucizumab[4]

End point description:

RP2D was determined based on Part I of the study. Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication.

End point type	Primary

End point timeframe:

From Day 1 until Day 28 of Cycle 1 (cycle length=28 days)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

End point values	Part I: Selicrelumab 1-72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	59			
Units: mg				
number (not applicable)	16			

Statistical analyses

No statistical analyses for this end point

Primary: Parts I and II: Percentage of Participants With Adverse Events (AEs)

End point title	Parts I and II: Percentage of Participants With Adverse Events (AEs)[5]

End point description:

An adverse event (AE) is any untoward medical occurrence in a participant who received a pharmaceutical product, and which did not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Any new disease or preexisting conditions which worsen during a study are also considered as adverse events. Safety analysis population included

all participants who enrolled in the study and received at least one dose of study medication.

End point type	Primary

End point timeframe:

From Day 1 of Cycle 1 until treatment discontinuation and safety follow up visit (45 days post-last dose; Cycle length=28 days) (up to approximately 42 months)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: percentage of participants				
number (not applicable)	100	100	100	100

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	11	13	
Units: percentage of participants				
number (not applicable)	100	100	100	

Statistical analyses

No statistical analyses for this end point

Primary: Parts I and II: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Selicrelumab

End point title	Parts I and II: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Selicrelumab[6][7]

End point description:

Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication. Number analysed is number of participants with data available for analyses.

End point type	Primary

End point timeframe:

Predose (-1 hour [h]) on Day 2 of Cycles 1, 2, 3, 4, 7, and every 3 cycles until/at disease progression and/or 45 days after last dose (cycle length=28 days) (up to approximately 42 months)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: For Part II of the study the arms were combined as the selicrelumab dose was 16 mg in all arms in Part II.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	14	14	9	15
Units: percentage of participants				
number (not applicable)	0	7.1	0	0

End point values	Part II: Selicrelumab 16 mg + Bevacizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	32			
Units: percentage of participants				
number (not applicable)	5.7			

Statistical analyses

No statistical analyses for this end point

Primary: Part I: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Vanucizumab

End point title	Part I: Percentage of Participants With Anti-Drug Antibodies (ADAs) to Vanucizumab[8][9]

End point description:

Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication. Number analysed is number of participants with data available for analyses.

End point type	Primary

End point timeframe:

Predose (within 10 minutes [min] before infusion) on D1 of Cycles 1, 2 ,4, and every 2 cycles until/at disease progression and/or 45 days after last dose (cycle length=28 days) (up to approximately 42 months)

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study as vanucizumab was administered only in Part I.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	14	9	15
Units: percentage of participants				
number (not applicable)	0	0	0	0

Statistical analyses

No statistical analyses for this end point

Primary: Part II: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria

End point title	Part II: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria[10][11]

End point description:

Best overall response rate (ORR) was defined as the percentage of participants with confirmed complete response (CR) and partial response (PR) on two consecutive occasions >/=4 weeks apart, as determined by the investigator according to RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.

End point type	Primary

End point timeframe:

Baseline until first documentation of CR or PR, or participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part II of the study.

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	11	13	
Units: percentage of participants				
number (confidence interval 95%)	0 (0.00 to 28.49)	9.1 (0.23 to 41.28)	0 (0.00 to 24.71)	

Statistical analyses

No statistical analyses for this end point

Primary: Part II: Duration of Objective Response (DOR) per RECIST v1.1 Criteria

End point title	Part II: Duration of Objective Response (DOR) per RECIST v1.1 Criteria[12][13]

End point description:

DOR was defined as time from the first occurrence of a documented objective response to the time of

relapse or death from any cause. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication. This endpoint was analysed in participants who have a best overall response of CR or PR as defined per RECIST v1.1.

End point type	Primary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part II of the study.

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0[14]	1[15]	0[16]	
Units: days				
median (full range (min-max))	(to)	212.0 (212 to 212)	(to)	

Notes:

[14] - Only responders were analysed in this endpoint.

[15] - Only responders were analysed in this endpoint.

[16] - Only responders were analysed in this endpoint.

Statistical analyses

No statistical analyses for this end point

Primary: Part II: Percentage of Participants With Disease Control per RECIST v1.1 Criteria

End point title	Part II: Percentage of Participants With Disease Control per RECIST v1.1 Criteria[17][18]

End point description:

Disease control rate (DCR) was defined as the percentage of participants who achieved a best overall response of confirmed CR, confirmed PR or stable disease (SD) lasting at least 8 weeks per RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum of the diameters while on study. PD: at least 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline (nadir). Efficacy analysis population included all evaluable participants who enrolled in the study and received at least 1 dose of study medication.

End point type	Primary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline

period.

Justification: The endpoint is only reporting Part II of the study.

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	11	13	
Units: percentage of participants				
number (confidence interval 95%)	54.5 (23.38 to 83.25)	54.5 (23.38 to 83.25)	53.8 (25.13 to 80.78)	

Statistical analyses

No statistical analyses for this end point

Primary: Part II: Percentage of Participants With Clinical Benefit per RECIST v1.1 Criteria

End point title	Part II: Percentage of Participants With Clinical Benefit per RECIST v1.1 Criteria[19][20]

End point description:

Clinical Benefit Rate (CBR) was defined as the percentage of participants who achieved a best overall response of confirmed CR, confirmed PR or SD per RECIST 1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline (nadir). Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.

End point type	Primary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint.

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is only reporting Part II of the study.

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	11	13	
Units: percentage of participants				
number (confidence interval 95%)	63.6 (30.79 to 89.07)	72.7 (39.03 to 93.98)	61.5 (31.58 to 86.14)	

Statistical analyses

No statistical analyses for this end point

Primary: Part II: Progression-free Survival (PFS) per RECIST v1.1 Criteria

End point title	Part II: Progression-free Survival (PFS) per RECIST v1.1 Criteria[21][22]

End point description:

PFS was defined as time from start of treatment to radiographical disease progression or death, whichever occurred first. Per RECIST v1.1, progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If no disease progression was recorded and no death occurred within 100 days from last tumor assessment, participants were censored at the last tumor assessment. If no post baseline tumor assessment was performed, participants were not evaluable. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.99999 denotes the upper limit of CI which was not estimable due to censored observations.

End point type	Primary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses were performed for this endpoint.

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part II of the study.

End point values	Part II: Selicrelumab + Bevacizumab (HNSCC)	Part II: Selicrelumab + Bevacizumab (NSCLC)	Part II: Selicrelumab + Bevacizumab (aPROC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	11	11	13	
Units: days				
median (confidence interval 95%)	107.0 (51.0 to 109.0)	103.0 (55.0 to 139.0)	114.0 (50.0 to 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of Selicrelumab Following Subcutaneous (SC) Administration [Cycle 1]

End point title	Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of Selicrelumab Following Subcutaneous (SC) Administration [Cycle 1]

End point description:

Pharmacokinetic (PK) analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 1, Day 2: predose (-1 h), 4, 8, 24, 48, 72 h postdose; Part II: Cycle 1, Day 1: predose (-1 h), 24, 48, 72 h postdose, Day 8 and predose (-10 minutes) on Day 15

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: microgram*hour per milliliter (mcg.h/mL)				
arithmetic mean (standard deviation)	1.46 (± 9999)	4.07 (± 0.81)	6.30 (± 4.52)	11.52 (± 7.65)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: microgram*hour per milliliter (mcg.h/mL)				
arithmetic mean (standard deviation)	23.12 (± 6.89)	24.21 (± 12.12)	34.16 (± 16.13)	30.78 (± 16.52)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4
Units: microgram*hour per milliliter (mcg.h/mL)				
arithmetic mean (standard deviation)	67.22 (± 29.46)	59.75 (± 40.44)	101.43 (± 37.84)	86.41 (± 65.49)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			

Number of subjects analysed	7			
Units: microgram*hour per milliliter (mcg.h/mL)				
arithmetic mean (standard deviation)	132.15 (± 71.86)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of Selicrelumab Following SC Administration [Cycle 3]

End point title	Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUClast) of Selicrelumab Following SC Administration [Cycle 3]

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 3, Day 2: predose (-1 h) and 8h postdose; Part II: Cycle 3, Day 1: predose (-1 h)

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	1	4
Units: mcg.h/mL				
arithmetic mean (standard deviation)	2.49 (± 9999)	5.62 (± 0.41)	11.32 (± 9999)	21.10 (± 2.03)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: mcg.h/mL				
arithmetic mean (standard deviation)	33.51 (± 9.7)	59.45 (± 46.86)	53.43 (± 6.41)	70.89 (± 26.36)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	1	4
Units: mcg.h/mL				
arithmetic mean (standard deviation)	138.55 (± 142.93)	126.17 (± 63.11)	127.02 (± 9999)	204.10 (± 82.55)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: mcg.h/mL				
arithmetic mean (standard deviation)	323.49 (± 111.71)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Concentration (Cmax) of Selicrelumab Following SC Administration [Cycle 1]

End point title	Maximum Concentration (Cmax) of Selicrelumab Following SC Administration [Cycle 1]

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 1, Day 2: predose (-1 h), 4, 8, 24, 48, 72 h postdose; Part II: Cycle 1, Day 1: predose (-1 h), 24, 48, 72 h postdose, Day 8 and predose (-10 minutes) on Day 15

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	0.0019 (± 9999)	0.0040 (± 0.0004)	0.0070 (± 0.0048)	0.0127 (± 0.0037)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	0.0257 (± 0.0132)	0.0269 (± 0.0244)	0.0407 (± 0.0209)	0.0448 (± 0.0179)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4
Units: microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	0.0801 (± 0.053)	0.0738 (± 0.0224)	0.1109 (± 0.0389)	0.1322 (± 0.061)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: microgram per milliliter (mcg/mL)				
arithmetic mean (standard deviation)	0.1628 (± 0.0768)			

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Concentration (Cmax) of Selicrelumab Following SC Administration [Cycle 3]

End point title	Maximum Concentration (Cmax) of Selicrelumab Following SC Administration [Cycle 3]

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 3, Day 2: predose (-1 h) and 8h postdose; Part II: Cycle 3, Day 1: predose (-1 h)

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	1	4
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0029 (± 9999)	0.0055 (± 0.0004)	0.0082 (± 9999)	0.0149 (± 0.0062)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0260 (± 0.0024)	0.0764 (± 0.067)	0.0567 (± 0.0116)	0.0682 (± 0.0362)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	1	4
Units: mcg/mL				
arithmetic mean (standard deviation)	0.1075 (± 0.0888)	0.0899 (± 0.0112)	0.1177 (± 9999)	0.2044 (± 0.1304)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: mcg/mL				
arithmetic mean (standard deviation)	0.3726 (± 0.1665)			

Statistical analyses

No statistical analyses for this end point

Secondary: Trough Concentration (Ctrough) of Selicrelumab Following SC Administration [Cycle 1]

End point title	Trough Concentration (Ctrough) of Selicrelumab Following SC Administration [Cycle 1]

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 1, Day 2: predose (-1 h), 4, 8, 24, 48, 72 h postdose; Part II: Cycle 1, Day 1: predose (-1 h), 24, 48, 72 h postdose, Day 8 and predose (-10 minutes) on Day 15

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0019 (± 9999)	0.0040 (± 0.0004)	0.0070 (± 0.0048)	0.0127 (± 0.0037)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0257 (± 0.0132)	0.0269 (± 0.0244)	0.0467 (± 0.0207)	0.0449 (± 0.0178)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0801 (± 0.053)	0.0739 (± 0.0224)	0.1110 (± 0.0389)	0.1322 (± 0.061)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: mcg/mL				
arithmetic mean (standard deviation)	0.1629 (± 0.0768)			

Statistical analyses

No statistical analyses for this end point

Secondary: Trough Concentration (Ctrough) of Selicrelumab Following SC Administration [Cycle 3]

End point title	Trough Concentration (Ctrough) of Selicrelumab Following SC Administration [Cycle 3]

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint. 9999 denotes SD which was not estimable for 1 participant.

End point type	Secondary

End point timeframe:

Part I: Cycle 3, Day 2: predose (-1 h) and 8h postdose; Part II: Cycle 3, Day 1: predose (-1 h)

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0029 (± 9999)	0.0055 (± 0.0004)	0.0068 (± 0.0021)	0.0109 (± 0.0082)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: mcg/mL				
arithmetic mean (standard deviation)	0.0260 (± 0.0024)	0.0763 (± 0.0672)	0.0524 (± 0.0114)	0.0530 (± 0.0436)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4

Units: mcg/mL				
arithmetic mean (standard deviation)	0.0938 (± 0.0775)	0.1042 (± 0.03)	0.1630 (± 0.0639)	0.2044 (± 0.1304)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: mcg/mL				
arithmetic mean (standard deviation)	0.3729 (± 0.1666)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Maximum Concentration (Tmax) of Selicrelumab Following SC Administration

End point title	Time to Maximum Concentration (Tmax) of Selicrelumab Following SC Administration

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint.

End point type	Secondary

End point timeframe:

Part I: Cycle 1, Day 2: predose (-1 h), 4, 8, 24, 48, 72 h postdose, Cycle 3, Day 2: predose (-1 h) and 8h postdose; Part II: Cycle 1, Day 1: predose (-1 h), 24, 48, 72 h postdose, Day 8 and predose (-10 minutes) on Day 15, Cycle 3, Day 1: predose (-1 h)

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: hours (h)				
median (full range (min-max))	72.00 (72.00 to 72.00)	649.34 (71.93 to 695.23)	48.01 (46.62 to 49.00)	59.57 (45.38 to 165.17)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6

Units: hours (h)				
median (full range (min-max))	71.42 (47.67 to 844.27)	48.57 (47.83 to 671.25)	164.15 (72.13 to 336.38)	192.63 (48.17 to 673.53)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4
Units: hours (h)				
median (full range (min-max))	48.65 (47.83 to 670.92)	70.72 (48.25 to 671.50)	69.83 (46.33 to 358.35)	179.84 (47.50 to 671.88)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hours (h)				
median (full range (min-max))	669.83 (48.83 to 940.00)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time Taken to Achieve the First Quantifiable Plasma Concentration of Selicrelumab Following SC Administration

End point title	Time Taken to Achieve the First Quantifiable Plasma Concentration of Selicrelumab Following SC Administration

End point description:

PK analysis population included participants who received at least one dose of selicrelumab during the study and had at least 3 quantifiable plasma concentrations post selicrelumab administration. Number analysed is number of participants with data available for analyses at the given timepoint.

End point type	Secondary

End point timeframe:

Part I: Cycle 1, Day 2: predose (-1 h), 4, 8, 24, 48, 72 h postdose, Cycle 3, Day 2: predose (-1 h) and 8h postdose; Part II: Cycle 1, Day 1: predose (-1 h), 24, 48, 72 h postdose, Day 8 and predose (-10 minutes) on Day 15, Cycle 3, Day 1: predose (-1 h)

End point values	Selicrelumab 1 mg + Vanucizumab	Selicrelumab 2 mg + Vanucizumab	Selicrelumab 4 mg + Vanucizumab	Selicrelumab 8 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	1	4	4	4
Units: hours (h)				
median (full range (min-max))	72.00 (72.00 to 72.00)	348.33 (24.25 to 673.70)	8.00 (4.05 to 8.08)	14.12 (4.05 to 48.13)

End point values	Selicrelumab 12 mg + Vanucizumab	Selicrelumab 14 mg + Vanucizumab	Part II: Selicrelumab 16 mg + Bevacizumab	Selicrelumab 18 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	3	19	6
Units: hours (h)				
median (full range (min-max))	4.03 (4.00 to 8.00)	4.00 (3.98 to 4.13)	23.48 (20.55 to 140.75)	4.09 (3.95 to 8.08)

End point values	Selicrelumab 24 mg + Vanucizumab	Selicrelumab 32 mg + Vanucizumab	Selicrelumab 40 mg + Vanucizumab	Selicrelumab 48 mg + Vanucizumab
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	5	5	7	4
Units: hours (h)				
median (full range (min-max))	4.00 (3.98 to 8.00)	4.00 (4.00 to 4.03)	24.05 (4.00 to 25.00)	24.13 (24.00 to 25.00)

End point values	Selicrelumab 72 mg + Vanucizumab			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hours (h)				
median (full range (min-max))	24.17 (3.98 to 25.08)			

Statistical analyses

No statistical analyses for this end point

Secondary: Part I: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria

End point title	Part I: Percentage of Participants With Best Overall Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria[23]

End point description:

Best overall response rate (ORR) was defined as the percentage of participants with confirmed complete response (CR) and partial response (PR) on two consecutive occasions >/=4 weeks apart, as determined by the investigator according to RECIST v1.1. CR: Disappearance of all target and non-target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

Baseline until first documentation of CR or PR, or participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: percentage of participants				
number (confidence interval 95%)	0 (0.00 to 20.59)	0 (0.00 to 23.16)	20.0 (2.52 to 55.61)	0 (0.00 to 17.65)

Statistical analyses

No statistical analyses for this end point

Secondary: Part I: Duration of Objective Response (DOR) per RECIST v1.1 Criteria

End point title	Part I: Duration of Objective Response (DOR) per RECIST v1.1 Criteria[24]

End point description:

DOR was defined as time from the first occurrence of a documented objective response to the time of relapse or death from any cause. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication. This endpoint was analysed in participants who have a best overall response of CR or PR as defined per RECIST v1.1.

End point type	Secondary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0[25]	0[26]	2	0[27]
Units: days				
median (full range (min-max))	(to)	(to)	618.0 (435 to 801)	(to)

Notes:

[25] - Only responders were analysed for this endpoint.

[26] - Only responders were analysed for this endpoint.

[27] - Only responders were analysed for this endpoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Part I: Percentage of Participants With Disease Control per RECIST v1.1 Criteria

End point title	Part I: Percentage of Participants With Disease Control per RECIST v1.1 Criteria[28]

End point description:

Disease control rate (DCR) was defined as the percentage of participants who achieved a best overall response of confirmed CR, confirmed PR or SD lasting at least 8 weeks per RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline (nadir). Efficacy analysis population included all evaluable participants who enrolled in the study and received at least 1 dose of study medication.

End point type	Secondary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: percentage of participants				
number (confidence interval 95%)	50.0 (24.65 to 75.35)	57.1 (28.86 to 82.34)	80.0 (44.39 to 97.48)	31.6 (12.58 to 56.55)

Statistical analyses

No statistical analyses for this end point

Secondary: Part I: Percentage of Participants With Clinical Benefit per RECIST v1.1 Criteria

End point title	Part I: Percentage of Participants With Clinical Benefit per RECIST v1.1 Criteria[29]

End point description:

Clinical Benefit Rate (CBR) was defined as the percentage of participants who achieved a best overall response of confirmed CR, confirmed PR or SD per RECIST 1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline (nadir). Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: percentage of participants				
number (confidence interval 95%)	50.0 (24.65 to 75.35)	64.3 (35.14 to 87.24)	80.0 (44.39 to 97.48)	36.8 (16.29 to 61.64)

Statistical analyses

No statistical analyses for this end point

Secondary: Part I: Progression-free Survival (PFS) per RECIST v1.1 Criteria

End point title	Part I: Progression-free Survival (PFS) per RECIST v1.1

End point description:

PFS was defined as time from start of treatment to radiographical disease progression or death, whichever occurred first. Per RECIST v1.1, progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. If no disease progression was recorded and no death occurred within 100 days from last tumor assessment, participants were censored at the last tumor assessment. If no post baseline tumor assessment was performed, participants were not evaluable. Efficacy analysis population included all evaluable participants who enrolled in the study and received at least one dose of study medication.

End point type	Secondary

End point timeframe:

Baseline until participant's discontinuation or death, whichever occurs first (up to approximately 42 months)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline

period.

Justification: The endpoint is only reporting Part I of the study.

End point values	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	14	10	19
Units: days				
median (confidence interval 95%)	89.0 (53.0 to 128.0)	116.0 (57.0 to 162.0)	165.0 (98.0 to 230.0)	57.0 (50.0 to 113.0)

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

From Day 1 of Cycle 1 until treatment discontinuation and safety follow up visit (45 days post-last dose; Cycle length=28 days) (up to approximately 42 months)

Adverse event reporting additional description:

Safety analysis population included all participants who enrolled in the study and received at least one dose of study medication.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.1

Reporting groups

Reporting group title	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 1-8 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 24-32 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 12-18 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Part II: Selicrelumab + Bevacizumab (HNSCC)

Reporting group description:

Participants diagnosed with head and neck squamous cell carcinoma (HNSCC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab

Reporting group description:

Participants received a fixed dose of vanucizumab, 2 g via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 40-72 mg, subcutaneous (SC) injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment continued as long as the participant experienced clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (approximately 24 months). Due to the discontinuation of vanucizumab development, participants ongoing in Part I switched from vanucizumab to bevacizumab. All the dose escalations were performed using vanucizumab.

Reporting group title	Part II: Selicrelumab + Bevacizumab (aPROC)

Reporting group description:

Participants diagnosed with advanced platinum-resistant ovarian cancer (aPROC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Reporting group title	Part II: Selicrelumab + Bevacizumab (NSCLC)

Reporting group description:

Participants diagnosed with checkpoint-inhibitor (CPI)-experienced non-squamous non-small cell lung cancer (NSCLC) received bevacizumab 10 mg/kg via IV infusion on Days 1 and 15 of every 28-day cycle followed by selicrelumab 16 mg via SC injection on Day 2 of Cycles 1 to 4 and every third cycle thereafter until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or end of Part II of the study (i.e. approximately 18 months).

Serious adverse events	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 16 (68.75%)	6 / 10 (60.00%)	4 / 14 (28.57%)
number of deaths (all causes)	12	7	10
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain herniation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection related reaction			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchial fistula			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to	0 / 0	0 / 0	0 / 0

treatment / all			
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vision blurred			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Constipation			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	2 / 16 (12.50%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part II: Selicrelumab + Bevacizumab (HNSCC)	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab	Part II: Selicrelumab + Bevacizumab (aPROC)
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 11 (36.36%)	7 / 19 (36.84%)	4 / 13 (30.77%)
number of deaths (all causes)	6	16	7
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Brain herniation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injection related reaction			

subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Respiratory, thoracic and mediastinal disorders			
Bronchial fistula			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)

occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Intestinal perforation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	2 / 13 (15.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Large intestine perforation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Product issues			
Device occlusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)

occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)

occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Part II: Selicrelumab + Bevacizumab (NSCLC)		
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 11 (36.36%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events			
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Brain herniation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injection related reaction			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			

subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Bronchial fistula			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumothorax			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Posterior reversible encephalopathy syndrome				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal cord compression				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Eye disorders				
Vision blurred				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Abdominal pain				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ascites				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dysphagia				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Intestinal perforation				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine perforation				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal pain				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal haemorrhage				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				

Cholecystitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Drug-induced liver injury			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Product issues			
Device occlusion			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		

deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular device infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Cohorts 1-4: Selicrelumab 1-8 mg + Vanucizumab	Cohorts 8-9: Selicrelumab 24-32 mg + Vanucizumab	Cohorts 5-7: Selicrelumab 12-18 mg + Vanucizumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	16 / 16 (100.00%)	10 / 10 (100.00%)	14 / 14 (100.00%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 16 (0.00%)	2 / 10 (20.00%)	1 / 14 (7.14%)
occurrences (all)	0	2	2

Hot flush			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	7 / 16 (43.75%)	3 / 10 (30.00%)	7 / 14 (50.00%)
occurrences (all)	10	3	7
Hypotension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Jugular vein thrombosis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Pallor			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
White coat hypertension			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Infected neoplasm			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin neoplasm bleeding			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Tumour haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tumour pain			

subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 16 (25.00%)	2 / 10 (20.00%)	0 / 14 (0.00%)
occurrences (all)	6	2	0
Axillary pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Chest pain			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	3	0	0
Chills			
subjects affected / exposed	2 / 16 (12.50%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	2	1	3
Early satiety			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Face oedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	8 / 16 (50.00%)	4 / 10 (40.00%)	7 / 14 (50.00%)
occurrences (all)	8	6	7
Granuloma			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	2 / 16 (12.50%)	1 / 10 (10.00%)	3 / 14 (21.43%)
occurrences (all)	2	1	4
Infusion site pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences (all)	1	0	0
Injection site reaction			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Mucosal inflammation			
subjects affected / exposed	2 / 16 (12.50%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	2	1	1
Non-cardiac chest pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Oedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	2 / 16 (12.50%)	4 / 10 (40.00%)	1 / 14 (7.14%)
occurrences (all)	2	5	1
Pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Pyrexia			
subjects affected / exposed	8 / 16 (50.00%)	9 / 10 (90.00%)	11 / 14 (78.57%)
occurrences (all)	12	21	19
Swelling			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Anxiety			

subjects affected / exposed	2 / 16 (12.50%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	3	1	0
Delirium			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	3 / 16 (18.75%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	3	1	0
Sleep disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Pelvic pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Epicondylitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Fall			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			

subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	4
Injection related reaction			
subjects affected / exposed	14 / 16 (87.50%)	10 / 10 (100.00%)	14 / 14 (100.00%)
occurrences (all)	32	31	36
Post procedural oedema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 16 (25.00%)	2 / 10 (20.00%)	1 / 14 (7.14%)
occurrences (all)	4	4	1
Amylase increased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			
subjects affected / exposed	3 / 16 (18.75%)	2 / 10 (20.00%)	1 / 14 (7.14%)
occurrences (all)	4	3	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Blood creatinine increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood iron decreased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Body temperature increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	4 / 16 (25.00%)	2 / 10 (20.00%)	2 / 14 (14.29%)
occurrences (all)	4	3	3
Weight increased			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Bradycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cardiac failure			

subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Sinus tachycardia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Aphonia			
subjects affected / exposed	0 / 16 (0.00%)	2 / 10 (20.00%)	0 / 14 (0.00%)
occurrences (all)	0	3	0
Cough			
subjects affected / exposed	5 / 16 (31.25%)	2 / 10 (20.00%)	4 / 14 (28.57%)
occurrences (all)	6	4	6
Dysphonia			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	1
Dyspnoea			
subjects affected / exposed	3 / 16 (18.75%)	2 / 10 (20.00%)	4 / 14 (28.57%)
occurrences (all)	4	2	4
Dyspnoea exertional			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Hiccups			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0

Nasal congestion			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	2
Oropharyngeal pain			
subjects affected / exposed	1 / 16 (6.25%)	3 / 10 (30.00%)	1 / 14 (7.14%)
occurrences (all)	1	4	1
Pleural effusion			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	5	0	0
Pleuritic pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Productive cough			
subjects affected / exposed	0 / 16 (0.00%)	2 / 10 (20.00%)	1 / 14 (7.14%)
occurrences (all)	0	3	1
Pulmonary embolism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Lymphadenitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 16 (6.25%)	3 / 10 (30.00%)	3 / 14 (21.43%)
occurrences (all)	1	3	4
Dysaesthesia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Dysgeusia			
subjects affected / exposed	2 / 16 (12.50%)	3 / 10 (30.00%)	0 / 14 (0.00%)
occurrences (all)	2	3	0
Headache			
subjects affected / exposed	5 / 16 (31.25%)	4 / 10 (40.00%)	3 / 14 (21.43%)
occurrences (all)	7	8	3
Hyperaesthesia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Neuralgic amyotrophy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Peripheral motor neuropathy			

subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Peripheral sensory neuropathy			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	2	0	1
Peroneal nerve palsy			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Sciatica			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Somnolence			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Spinal cord compression			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Taste disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Diplopia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Dry eye			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Growth of eyelashes			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Periorbital oedema			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0

Photophobia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Tinnitus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	3	0	0
Abdominal pain			
subjects affected / exposed	2 / 16 (12.50%)	5 / 10 (50.00%)	2 / 14 (14.29%)
occurrences (all)	3	5	4
Abdominal pain upper			
subjects affected / exposed	3 / 16 (18.75%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	4	1	0
Anal fissure			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Anal haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Ascites			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Breath odour			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	3 / 16 (18.75%)	1 / 10 (10.00%)	5 / 14 (35.71%)

occurrences (all)	4	1	8
Diarrhoea			
subjects affected / exposed	5 / 16 (31.25%)	3 / 10 (30.00%)	2 / 14 (14.29%)
occurrences (all)	7	3	2
Dry mouth			
subjects affected / exposed	2 / 16 (12.50%)	2 / 10 (20.00%)	0 / 14 (0.00%)
occurrences (all)	2	2	0
Dyspepsia			
subjects affected / exposed	3 / 16 (18.75%)	3 / 10 (30.00%)	1 / 14 (7.14%)
occurrences (all)	3	3	1
Dysphagia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
Epigastric discomfort			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Glossodynia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ileus			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)

occurrences (all)	0	0	1
Impaired gastric emptying			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	11 / 16 (68.75%)	4 / 10 (40.00%)	6 / 14 (42.86%)
occurrences (all)	19	7	10
Noninfective gingivitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Oesophageal pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Oral cavity fistula			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Oral discomfort			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Small intestinal obstruction			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences (all)	2	0	0
Vomiting			
subjects affected / exposed	5 / 16 (31.25%)	3 / 10 (30.00%)	4 / 14 (28.57%)
occurrences (all)	10	3	6
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Proteinuria			
subjects affected / exposed	1 / 16 (6.25%)	2 / 10 (20.00%)	1 / 14 (7.14%)
occurrences (all)	1	5	1
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hepatic pain			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
Dry skin			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
Erythema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hidradenitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hyperhidrosis			
subjects affected / exposed	1 / 16 (6.25%)	2 / 10 (20.00%)	0 / 14 (0.00%)
occurrences (all)	1	2	0
Night sweats			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	1	1	0
Rash			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Skin disorder			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Skin odour abnormal			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 16 (6.25%)	3 / 10 (30.00%)	2 / 14 (14.29%)
occurrences (all)	1	3	3
Back pain			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	2	1	1
Bone pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	1 / 16 (6.25%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	1	1	1
Groin pain			

subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Muscle spasms			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Musculoskeletal pain			
subjects affected / exposed	4 / 16 (25.00%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	5	2	1
Myalgia			
subjects affected / exposed	3 / 16 (18.75%)	2 / 10 (20.00%)	3 / 14 (21.43%)
occurrences (all)	3	2	4
Neck pain			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
Pathological fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	5 / 16 (31.25%)	7 / 10 (70.00%)	5 / 14 (35.71%)
occurrences (all)	8	9	8
Dehydration			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)

occurrences (all)	1	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Hyponatraemia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Hypophosphataemia			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Carbuncle			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Cystitis			

subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Furuncle			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Gingivitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lymphadenitis bacterial			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	3	0
Omphalitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Periodontitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Pharyngitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pneumonia			

subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Pustule			
subjects affected / exposed	1 / 16 (6.25%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Rash pustular			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Respiratory tract infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 10 (10.00%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Tooth abscess			
subjects affected / exposed	0 / 16 (0.00%)	0 / 10 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	3 / 16 (18.75%)	1 / 10 (10.00%)	1 / 14 (7.14%)
occurrences (all)	4	1	1
Upper respiratory tract infection			
subjects affected / exposed	2 / 16 (12.50%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	3	0	1
Urinary tract infection			
subjects affected / exposed	3 / 16 (18.75%)	0 / 10 (0.00%)	1 / 14 (7.14%)
occurrences (all)	3	0	3

Non-serious adverse events	Part II: Selicrelumab + Bevacizumab (HNSCC)	Cohorts 10-12: Selicrelumab 40-72 mg +Vanucizumab	Part II: Selicrelumab + Bevacizumab (aPROC)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	19 / 19 (100.00%)	13 / 13 (100.00%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Flushing			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)

occurrences (all)	0	1	0
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	4 / 11 (36.36%)	8 / 19 (42.11%)	1 / 13 (7.69%)
occurrences (all)	4	16	2
Hypotension			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Jugular vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Lymphoedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
White coat hypertension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Infected neoplasm			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Skin neoplasm bleeding			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0

Tumour pain			
subjects affected / exposed	0 / 11 (0.00%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	0	2	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	4 / 19 (21.05%)	3 / 13 (23.08%)
occurrences (all)	0	5	4
Axillary pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	1	1	1
Chills			
subjects affected / exposed	2 / 11 (18.18%)	3 / 19 (15.79%)	1 / 13 (7.69%)
occurrences (all)	2	4	1
Early satiety			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	5 / 11 (45.45%)	7 / 19 (36.84%)	5 / 13 (38.46%)
occurrences (all)	7	8	5
Granuloma			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 11 (0.00%)	5 / 19 (26.32%)	1 / 13 (7.69%)
occurrences (all)	0	5	1
Infusion site pain			

subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Injection site reaction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	1 / 11 (9.09%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	1	2	0
Mucosal inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	0	2	1
Oedema peripheral			
subjects affected / exposed	0 / 11 (0.00%)	4 / 19 (21.05%)	1 / 13 (7.69%)
occurrences (all)	0	4	2
Pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	3 / 11 (27.27%)	5 / 19 (26.32%)	4 / 13 (30.77%)
occurrences (all)	5	7	7
Swelling			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Temperature intolerance			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0

Anxiety			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Delirium			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Insomnia			
subjects affected / exposed	0 / 11 (0.00%)	3 / 19 (15.79%)	0 / 13 (0.00%)
occurrences (all)	0	3	0
Sleep disorder			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Epicondylitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Infusion related reaction			

subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Injection related reaction			
subjects affected / exposed	10 / 11 (90.91%)	15 / 19 (78.95%)	13 / 13 (100.00%)
occurrences (all)	24	32	19
Post procedural oedema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Stoma site haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	8 / 19 (42.11%)	3 / 13 (23.08%)
occurrences (all)	2	13	4
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 11 (9.09%)	7 / 19 (36.84%)	3 / 13 (23.08%)
occurrences (all)	1	10	4
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Blood creatinine increased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Blood iron decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0

Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	2 / 13 (15.38%)
occurrences (all)	0	1	2
Lipase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	4 / 11 (36.36%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	4	1	0
Weight increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	1	1	0
Bradycardia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Cardiac failure			

subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Sinus bradycardia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Sinus tachycardia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Aphonia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Cough			
subjects affected / exposed	4 / 11 (36.36%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	5	1	1
Dysphonia			
subjects affected / exposed	3 / 11 (27.27%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	3	2	0
Dyspnoea			
subjects affected / exposed	1 / 11 (9.09%)	3 / 19 (15.79%)	2 / 13 (15.38%)
occurrences (all)	2	3	3
Dyspnoea exertional			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Hiccups			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0

Nasal congestion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Pleuritic pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Wheezing			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	1	1	1
Lymphadenitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)

occurrences (all)	0	1	1
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 19 (10.53%)	1 / 13 (7.69%)
occurrences (all)	0	4	1
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	0 / 11 (0.00%)	2 / 19 (10.53%)	1 / 13 (7.69%)
occurrences (all)	0	3	1
Dysaesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	2	0
Headache			
subjects affected / exposed	1 / 11 (9.09%)	5 / 19 (26.32%)	1 / 13 (7.69%)
occurrences (all)	1	11	1
Hyperaesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Neuralgic amyotrophy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Peripheral motor neuropathy			

subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 11 (0.00%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	0	3	0
Peroneal nerve palsy			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Spinal cord compression			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	3	0
Growth of eyelashes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0

Photophobia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	0	2	0
Abdominal pain			
subjects affected / exposed	2 / 11 (18.18%)	5 / 19 (26.32%)	4 / 13 (30.77%)
occurrences (all)	2	6	4
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Anal fissure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Anal haemorrhage			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Ascites			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Breath odour			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	6 / 11 (54.55%)	6 / 19 (31.58%)	4 / 13 (30.77%)

occurrences (all)	8	7	4
Diarrhoea			
subjects affected / exposed	1 / 11 (9.09%)	4 / 19 (21.05%)	5 / 13 (38.46%)
occurrences (all)	2	4	6
Dry mouth			
subjects affected / exposed	1 / 11 (9.09%)	3 / 19 (15.79%)	0 / 13 (0.00%)
occurrences (all)	1	5	0
Dyspepsia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	1	0	1
Dysphagia			
subjects affected / exposed	2 / 11 (18.18%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	3	1	0
Epigastric discomfort			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorder			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Glossodynia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Ileus			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)

occurrences (all)	0	0	0
Impaired gastric emptying			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	5 / 11 (45.45%)	7 / 19 (36.84%)	5 / 13 (38.46%)
occurrences (all)	5	9	6
Noninfective gingivitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Odynophagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oesophageal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oral cavity fistula			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oral discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Oral pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Small intestinal obstruction			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Stomatitis			
subjects affected / exposed	1 / 11 (9.09%)	2 / 19 (10.53%)	0 / 13 (0.00%)
occurrences (all)	1	2	0
Toothache			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)

occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	1 / 11 (9.09%)	6 / 19 (31.58%)	2 / 13 (15.38%)
occurrences (all)	4	7	5
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hepatic pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Erythema			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Hidradenitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Night sweats			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	1	1	1
Rash maculo-papular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	4 / 11 (36.36%)	4 / 19 (21.05%)	0 / 13 (0.00%)
occurrences (all)	5	4	0
Back pain			
subjects affected / exposed	1 / 11 (9.09%)	3 / 19 (15.79%)	3 / 13 (23.08%)
occurrences (all)	1	3	3
Bone pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Groin pain			

subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	4	1	1
Myalgia			
subjects affected / exposed	1 / 11 (9.09%)	7 / 19 (36.84%)	1 / 13 (7.69%)
occurrences (all)	1	7	1
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	1 / 13 (7.69%)
occurrences (all)	0	1	1
Pathological fracture			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Tendonitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	2	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 11 (9.09%)	6 / 19 (31.58%)	3 / 13 (23.08%)
occurrences (all)	3	8	6
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)

occurrences (all)	1	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Hypermagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 19 (5.26%)	2 / 13 (15.38%)
occurrences (all)	1	1	2
Hypomagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	2 / 13 (15.38%)
occurrences (all)	0	1	2
Hyponatraemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	2	0	1
Infections and infestations			
Carbuncle			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Cystitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Furuncle			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Localised infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Lymphadenitis bacterial			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Omphalitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Periodontitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Pharyngitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Pneumonia			

subjects affected / exposed	1 / 11 (9.09%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	1	0	0
Pustule			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	1 / 13 (7.69%)
occurrences (all)	0	0	1
Tooth infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 19 (5.26%)	0 / 13 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 19 (0.00%)	0 / 13 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 11 (9.09%)	2 / 19 (10.53%)	2 / 13 (15.38%)
occurrences (all)	3	2	3

Non-serious adverse events	Part II: Selicrelumab + Bevacizumab (NSCLC)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Flushing			
subjects affected / exposed	1 / 11 (9.09%)		

occurrences (all)	1		
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	3 / 11 (27.27%)		
occurrences (all)	4		
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Jugular vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Lymphoedema			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pallor			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
White coat hypertension			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	6		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Infected neoplasm			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Skin neoplasm bleeding			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Tumour haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Tumour pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Axillary pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Chills			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Early satiety			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	4 / 11 (36.36%)		
occurrences (all)	6		
Granuloma			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	4		
Infusion site pain			

subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Oedema			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	6 / 11 (54.55%)		
occurrences (all)	10		
Swelling			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Temperature intolerance			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Agitation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Anxiety			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Delirium			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Sleep disorder			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Menstruation irregular			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pelvic pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Vulvovaginal pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Epicondylitis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Infusion related reaction			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Injection related reaction			
subjects affected / exposed	10 / 11 (90.91%)		
occurrences (all)	20		
Post procedural oedema			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Stoma site haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Amylase increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Blood iron decreased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Body temperature increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Weight increased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Bradycardia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Cardiac failure			

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Palpitations			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Sinus bradycardia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Sinus tachycardia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Aphonia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	3		
Dysphonia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	4 / 11 (36.36%)		
occurrences (all)	4		
Dyspnoea exertional			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Nasal congestion			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pleuritic pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Upper-airway cough syndrome			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	2		
Lymphadenitis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)		

occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dysaesthesia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	5		
Hyperaesthesia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Neuralgic amyotrophy			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Peripheral motor neuropathy			

subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Peroneal nerve palsy			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Spinal cord compression			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Taste disorder			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Diplopia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Growth of eyelashes			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Periorbital oedema			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Photophobia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Tinnitus			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Anal fissure			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Anal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Anorectal discomfort			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Ascites			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Breath odour			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	2 / 11 (18.18%)		

occurrences (all)	2			
Diarrhoea				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	2			
Dry mouth				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Dyspepsia				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Dysphagia				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Epigastric discomfort				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Gastritis				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Gastrointestinal disorder				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Gastrointestinal pain				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Gastrooesophageal reflux disease				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Glossodynia				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Haemorrhoidal haemorrhage				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Ileus				
subjects affected / exposed	0 / 11 (0.00%)			

occurrences (all)	0			
Impaired gastric emptying				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Nausea				
subjects affected / exposed	3 / 11 (27.27%)			
occurrences (all)	3			
Noninfective gingivitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Odynophagia				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Oesophageal pain				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Oral cavity fistula				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Oral discomfort				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Oral pain				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Small intestinal obstruction				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Stomatitis				
subjects affected / exposed	3 / 11 (27.27%)			
occurrences (all)	3			
Toothache				
subjects affected / exposed	0 / 11 (0.00%)			

occurrences (all)	0		
Vomiting			
subjects affected / exposed	3 / 11 (27.27%)		
occurrences (all)	3		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hepatic pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hidradenitis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Night sweats			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Rash			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	3		
Rash maculo-papular			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Skin disorder			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Skin hyperpigmentation			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Skin odour abnormal			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	2 / 11 (18.18%)		
occurrences (all)	3		
Bone pain			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Flank pain			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Groin pain			

subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	5		
Neck pain			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Pathological fracture			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	2		
Tendonitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	5 / 11 (45.45%)		
occurrences (all)	6		
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)		

occurrences (all)	0		
Glucose tolerance impaired			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hypermagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	3 / 11 (27.27%)		
occurrences (all)	4		
Hypomagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hyponatraemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Carbuncle			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Cystitis			

subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Device related infection				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Furuncle				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Gingivitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Infection				
subjects affected / exposed	1 / 11 (9.09%)			
occurrences (all)	1			
Localised infection				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Lymphadenitis bacterial				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Nasopharyngitis				
subjects affected / exposed	2 / 11 (18.18%)			
occurrences (all)	2			
Omphalitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Oral candidiasis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Periodontitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Pharyngitis				
subjects affected / exposed	0 / 11 (0.00%)			
occurrences (all)	0			
Pneumonia				

subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Pustule			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Tooth abscess			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 August 2015	Protocol BP29889 was amended to include additional timepoints to the vanucizumab pharmacokinetic (PK) sample collection and to update the Systemic Immune Activation (SIA) wording to reflect the current in-house definition of SIA diagnosis and management.
21 February 2016	Protocol was amended to update inclusion and exclusion criteria to include the consolidated risk mitigation measures regarding gastrointestinal perforation (GIP) applied to all participants treated with vanucizumab and to align with previous and ongoing vanucizumab studies.
19 December 2016	Injection site reactions (Grade 3) following subcutaneous (SC) administration of RO7009789 were documented in this study and in Study BP29392. These reactions occurred at dose levels below the previously defined maximum tolerated dose of RO7009789 when given intravenously (IV) (0.2 mg/kg or 16 mg). To mitigate potential injection-site toxicity, the text was modified to 1) split the injection into multiple injections at different anatomical sites at any dose level and 2) potentially allow IV administration of RO7009789 to explore safer or more efficacious administration.
29 December 2017	Protocol was amended to include the generic name selicrelumab for RO7009789 and Optimal Biological Dose (OBD) had been incorporated together with the Maximum Tolerated Dose (MTD), in the event the recommended dose was lower than the MTD (if reached) and could be defined by pharmacodynamic and/or clinical/efficacy assessments. Also to add bevacizumab in the protocol when describing the combination partner to RO7009789 together with vanucizumab (e.g., RO7009789 and vanucizumab or bevacizumab).
15 November 2018	Protocol was amended due to the discontinuation of vanucizumab development. Vanucizumab was replaced by bevacizumab in participants enrolled in Part I of the study who were ongoing. New version of selicrelumab with an updated manufacturing process, Ro 700-9789/F04 was provided.
22 May 2019	Protocol was amended to update the management guidelines for treatment of injection site reactions to make consistent with updated treatment guidelines described in other study protocols including treatment with selicrelumab (i.e., Studies BP29392, WO39608, CO40115, and CO39612).

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
30 October 2019	The study was terminated prematurely due to the Sponsor's decision to discontinue the clinical development of selicrelumab in combination with anti-angiogenic therapy as result of limited clinical benefit observed in the patient population in this study.	-

Notes:

Limitations and caveats

None reported